RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on Nuclear Magnetic Resonance (NMR) technology, today announced the publication of a consensus statement in the current issue of the Journal of Clinical Lipidology by a panel of experts in the field of clinical lipidology that was convened by the National Lipid Association (NLA), a nonprofit, multidisciplinary medical society focused on enhancing the practice of lipid management in clinical medicine. The panel recommends testing for several cardiovascular biomarkers, including LDL particle number (LDL-P), for the clinical assessment and on-treatment management of cardiovascular disease (CVD) risk.
